[Revision surgery in episcleral glaucoma drainage devices].

A. Rosentreter,T. Dietlein

DOI: https://doi.org/10.1007/s00347-016-0334-5

Der Ophthalmologe

Abstract:

What problem does this paper attempt to address?

Optimal production and purification of n.c.a.143Pr as a promising palliative agent for the treatment of metastatic bone pain

Simindokht Shirvani-Arani,Hassan Ranjbar,Ali Bahrami-Samani

DOI: https://doi.org/10.1038/s41598-024-64321-z

IF: 4.6

2024-06-13

Scientific Reports

Abstract:This study proposes the beta-emitting radioisotope 143 Pr as a promising candidate for palliative treatment of metastatic bone pain due to its desirable physical decay characteristics. An optimized process was developed for the production and purification of non-carrier-added 143 Pr using a medium flux research reactor. Calculations were performed to determine the optimal irradiation time and cooling period for irradiating 1 mg of natural cerium oxide to indirectly produce 143 Pr through the decay of 143 Ce. Following irradiation and cooling, extraction chromatography was employed to efficiently isolate 143 Pr from the irradiated target material. A column containing Ln-resin was used along with nitric acid as the mobile phase and an optional oxidation step with NaBrO 3 /ascorbic acid to separate 143 Pr from impurities such as 143 Ce and 141 Ce. Radionuclidic purity of over 99.995% was achieved as confirmed through gamma spectroscopy, demonstrating effective separation of 143 Pr. Additional quality control analyses established the chemical and radiochemical purity of the purified 143 Pr nitrate product. With a half-life of 13.6 days and maximum beta energy of 0.937 MeV, 143 Pr exhibits favorable properties for palliative bone pain therapy. This study therefore provides a viable method for producing high-purity 143 Pr through the optimized irradiation and purification processes described. Further investigation is warranted to explore potential clinical applications of 143 Pr for palliation of metastatic bone cancer pain.

multidisciplinary sciences
Efficacy And Safety Of Lu-177-Edtmp In Bone Metastatic Pain Palliation In Breast Cancer And Hormone Refractory Prostate Cancer A Phase Ii Study

Jie Yuan,Congjin Liu,Xingdang Liu,Yuankai Wang,Dayu Kuai,Guangming Zhang,John J. Zaknun

DOI: https://doi.org/10.1097/RLU.0b013e318279bf4d

IF: 10.6

2013-01-01

Clinical Nuclear Medicine

Abstract:Purpose: Lu-177-labeled ethylenediamine-N,N,N',N'-tetrakis methylene phosphonic acid (Lu-177-EDTMP), was used to palliate metastatic bone pain as a new bone-seeking radiopharmaceutical. In this phase II study, we assessed the efficacy and safety of Lu-177-EDTMP for bone pain palliation in patients with breast cancer and hormone refractory prostate cancer with bone metastases.Methods: Sixteen patients were enrolled in the trial and were subsequently divided into 2 groups, the low-dose group (1295 MBq) and the high dose group (2590 MBq) to determine differences in toxicities and response rates. Pain scores, Karnofsky indices, mobility scores, and requirement of analgesic administration were assessed at 0, 2, 4, 6, 8, and 12 weeks after injection of Lu-177-EDTMP. Toxicity was assessed by analyzing hemoglobin, leukocyte, and platelet counts.Results: An obvious reduction in the mean pain score was observed at 2 to 6 weeks after the administration of Lu-177-EDTMP. The rate of complete responses in bone pain palliation was 55% in group 1 and 80% in group 2 at 6 weeks after treatment. Of the 5 patients who required additional analgesics, all were able to reduce or completely stop taking these medications by 4 weeks after therapy. Mean (SD) Karnofsky indices of 58.18 (9.82) (range, 50-70) and 56.00 (8.94) (range, 50-70) at baseline increased to 82.73 (9.05) (range, 60-90) at 6 weeks after Lu-177-EDTMP treatment in group 1 and 85.00 (5.77) (range, 80-90) at 8 weeks after injection in group 2, respectively. Mobility scores decreased from 2.91 (1.04) (range, 1-4) and 2.80 (0.84) (range, 2-4) at baseline to 1.00 (0.67) (range, 0-2) and 0.50 (0.58) (range, 0-1) at 8 weeks after administration of Lu-177-EDTMP in groups 1 and 2, respectively, primarily owing to improved mobility. In group 1, 1 patient experienced grade III toxicity in both hemoglobin and platelet counts. No grade IV toxicities were observed. In group 2, there were no grade III or IV toxicities found in hemoglobin, platelets, or leukocytes counts. Moreover, no clinically significant adverse effects were observed, and no significant differences in either efficacy or safety were detected between the 2 dose levels.Conclusions: This study indicated that Lu-177-EDTMP was an effective and safe treatment for palliation of metastatic bone pain in patients with prostate or breast cancer. A dose of 1295 MBq (35 mCi) was sufficient for bone pain palliation therapy, and doses as high as 2590 MBq (70 mCi) were well tolerated.
Effects of different doses 177Lu-EDTMP for painful bone metastases from prostate and breast cancer

xingdang liu,jie yuan,congjin liu,hongyu li,zhifu luo,john zaknun

2012-01-01

Journal of Nuclear Medicine

Abstract:1210 Objectives To explore efficacy and safety of the dose difference in 177Lu-EDTMP for painful bone metastases treatment from prostate cancer or breast cancer patients. Methods 18 patients were enrolled and 2 patients’ data were excluded from the analysis because of incomplete datasets. They all had bone pain and positive 99mTc-MDP bone scan consistent with metastatic bone lesions. The trial was divided into two groups. Group 1 received 1295 MBq (35mCi) 177Lu-EDTMP and Group 2 received 2580 MBq (70 mCi). Patients were examined and followed up at baseline and at 2, 4, 6, 8, 12 weeks. Results Group 1, 3 prostate and 8 breast cancer patients, aged 58.27±11.86 years (38-81) and Group 2, 5 prostate cancer patients, aged 76.60±5.86 years (69-84). Pain relief occurred in 90.91% of patients in Group 1 and 100% of patients in Group 2 at wk2 (P>0.05). Complete absence of pain occurred in 18.18% in Group 1 and 60% in Group 2 at wk12 (P>0.05). Pain scores fell by at least 50% of the pretreatment score in 80% in Group 1 and 75% in Group 2 at wk12 (P>0.05). Mean duration of pain relief was 2.45 mo in Group1 and 2.80 mo in Group 2. Improvement in quality of life was noted. Karnofsky index, mobility scores and analgesic scores fell along with the drop in pain scores. A fall in leukocyte count and platelet count occurred in 100% in Group 1 and 50% in Group 2 at wk2 (P>0.05). The fall in leukocyte count and platelet count occurred in 47.06% in Group 1 and 55.56% in Group 2 at wk12 (P>0.05). There was no significant difference between the two treatments in terms of either efficacy or toxicity. Conclusions This study indicated that 177Lu-EDTMP is an effective treatment for palliation of pain from bony metastases. There was no difference in painful bone metastases from prostate cancer or breast cancer patients with low- or high-dose 177Lu-EDTMP treatment in terms of either efficacy or toxicity. Research Support International Atomic Energy Agency Coordinated Research Project (CRP) E1.30.33, Research Contract Number 1526
A Comparative Study of Samarium-153-Ethylenediaminetetramethylene Phosphonic Acid with Pamidronate Disodium in the Treatment of Patients with Painful Metastatic Bone Cancer

RF Wang,CL Zhang,SL Zhu,M Zhu

DOI: https://doi.org/10.1159/000069120

2003-01-01

Medical Principles and Practice

Abstract:Objective: To assess the therapeutic efficacy and toxicity of samarium-153-ethylenediaminetetramethylene phosphonic acid (153Sm-EDTMP) and pamidronate disodium in patients with painful metastatic bone cancer. Subjects and Methods: Eighteen patients with histopathologically confirmed malignancy and multifocal bone metastases were randomized into two equal groups of 9 patients each. Group A was treated with 153Sm-EDTMP, while group B was treated with pamidronate disodium. The pain score for each patient was recorded before and after therapy using visual analogue scales that graded both the intensity and frequency of the bone pain. Therapeutic response was classified as inefficient, mild, effective and excellent. Results: Pain score in each group prior to therapy was more than 6. In group A, 2 (22.2%) and 7 (77.8%) cases showed mild and effective response, respectively. The therapeutic efficacy of 153Sm-EDTMP was adjudged to be 77.8%. Transient myelosuppression was generally mild and reversible with white blood cells and platelets recovering after 6 weeks. In group B, palliative response in 4 cases (44.4%) was inefficient, in 1 case (11.1%) mild, in 3 cases (33.3%) effective and in 1 case (11.1%) excellent, with a therapeutic efficacy of 44.4% for pamidronate disodium. No hematological toxicity was noted. Conclusion: The data showed that the therapeutic efficacy of 153Sm-EDTPM was higher than that of pamidronate disodium (for pain relief maintained more than 3 weeks) and its incidence of blood toxicity was also higher than that of pamidronate disodium.
Clinical observation of ~(153)Sm-EDTMP in treatment of painful bone metastasis in cancer patients

CHENG Ai-ping,CHEN Shao-liang

2009-01-01

Abstract:Objective To evaluate the efficacy and adverse effects of 153Sm-EDTMP in pain palliation of bone metastases in cancer patients.Method One hundred and three cancer patients with painful bone metastasis were treated by 153Sm-EDTMP(37 MBq/kg),and the pain-palliation effect,quality of life,and bone marrow function were studied.Visual analog scale(VAS) was conducted before and after treatment;and blood counts were performed weekly before and 4,6 and 8 weeks after treatment.Results Total 76% patients reported pain relief.VAS showed a maximal decrease at week 6 after treatment(P<0.05).Improvement on Karnofsky performance scale was reported,most predominant at week 4 after treatment(P<0.05).There was transient descent of blood cell counts,and returned to baseline levels at week 8 after treatment.Only patients who had myelosuppression before treatment might present grade Ⅲ toxicity.Conclusion 153Sm-EDTMP is effective in pain palliation without severe side effects,and it may improve the quality of life of patients.
177 Lu-Edtmp For Bone Pain Palliation In Metastatic Prostate And Breast Cancer: A Phase Ii Trial

X. Liu,C. Liu,H. Li,Z. Luo,Y. Wang,Z. J. John

2011-01-01

Journal of Nuclear Medicine

Abstract:1752 Objectives To assess safety and efficacy of 177Lu-EDTMP in bone pain palliation in breast and prostate cancer patients with bone metastases. Methods Subjects were treated with 177Lu-EDTMP. Criteria for entry into the trial was a positive 99mTc-MDP bone scan consistent with bony metastase pain.Life expectancy is more than 3mo. Results Eleven patients, 6 prostate and 5 breast cancer, aged 65.5±13.8yr (38-84 yr). Seven and four were received 1295 MBq (35mCi) and 2590MBq(70mCi) respectively. 11 patients mean bone lesion score was 14.18 (6-19). In platelet toxicity, 2(18%) of 11 patients developed grade I, 1(9%) developed grade III, 1(9%) developed grade IV. The mean nadir platelet count was 91,1111/mm3at the 4th wk and began to completely recovery from 6th wk; 1(9%) patient developed grade II leucocyte toxicity.The median nadir leucocyte counts was 4,352/mm3 at 2th wk and began to completely recovery from 6th wk. Two subjects did not provide the hematologic counts from 2th wk. Large dose caused more marrow suppression. Table 1 detailed all 11 patients responding almost at 2th wk by the observed trend of pain score, analgesic frequency, mobility, Kamofsky performance. Six, three and two of 11 patients had a duration of palliation of 3, 2, and 1 mo respectively. Conclusions This primarily trial indicated that 177Lu-EDTMP is an effective treatment for palliation of pain from bony metastases. More cases are now being recruited into this study to further examine the efficacy of 177Lu-EDTMP. Research Support IAEA.CRP.E1.30.33,No.1526
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT

Dagmar Grob,Bastiaan M. Privé,Constantijn H. J. Muselaers,Niven Mehra,James Nagarajah,Mark W. Konijnenberg,Steffie M. B. Peters

DOI: https://doi.org/10.1186/s40658-024-00636-0

2024-04-03

EJNMMI Physics

Abstract:Abstract Background Bone marrow toxicity in advanced prostate cancer patients who receive [ 177 Lu]Lu-PSMA-617 is a well-known concern. In early stage patients; e.g. low volume metastatic hormone sensitive prostate cancer (mHSPC) patients, prevention of late bone marrow toxicity is even more crucial due to longer life expectancy. To date, bone marrow dosimetry is primarily performed using blood sampling. This method is time consuming and does not account for possible active bone marrow uptake. Therefore other methodologies are investigated. We calculated the bone marrow absorbed dose for [ 177 Lu]Lu-PSMA-617 in mHSPC patients using SPECT/CT imaging and compared it to the blood sampling method as reference. Methods Eight mHSPC patients underwent two cycles (3 and 6 GBq) of [ 177 Lu]Lu-PSMA-617 therapy. After each cycle, five time point (1 h, 1 day, 2 days, 3 days, 7 days) SPECT/CT was performed at kidney level. Bone marrow dosimetry was performed using commercial software by drawing ten 1.5 cm diameter spheres in the lowest ten vertebrae to determine the time-integrated activity. Simplified protocols using only 2 imaging time points and 3 vertebrae were also compared. Blood-based dosimetry was based on the blood sampling method according to the EANM guideline. Results Mean bone marrow absorbed dose was significantly different ( p < 0.01) for the imaging based method (25.4 ± 8.7 mGy/GBq) and the blood based method (17.2 ± 3.4 mGy/GBq), with an increasing absorbed dose ratio between both methods over time. Bland Altman analysis of both simplification steps showed that differences in absorbed dose were all within the 95% limits of agreement. Conclusion This study showed that bone marrow absorbed dose after [ 177 Lu]Lu-PSMA-617 can be determined using an imaging-based method of the lower vertebrae, and simplified using 2 time points (1 and 7 days) and 3 vertebrae. An increasing absorbed dose ratio over time between the imaging-based method and blood-based method suggests that there might be specific bone marrow binding of [ 177 Lu]Lu-PSMA-617.

radiology, nuclear medicine & medical imaging
Samarium for osteoblastic bone metastases and osteosarcoma

Pete Anderson

DOI: https://doi.org/10.1517/14656566.7.11.1475

2006-07-21

Expert Opinion on Pharmacotherapy

Abstract:Samarium-153 lexidronam (153Sm-EDTMP) is FDA approved for painful osteoblastic bone metastases that image on bone scan. 153Sm-EDTMP decay has a therapeutic beta-emission and a gamma-photon for bone scan imaging. Monitoring of osteosarcoma radiation treatment effectiveness was performed with bone, CT, MRI and PET/CT fusion imaging. Bone scan and PET/CT improved in 5 out of 9 and 16 out of 18 osteosarcoma sites, respectively. 153Sm-EDTMP targets multiple sites of disease, with a single administration. Side effects of 153Sm-EDTMP (0.5-2.5 mCi/kg) have been minimal and include transient thrombocytopenia and neutropenia. 153Sm-EDTMP can be combined with radiation therapy, bisphosphonates and/or chemotherapy to synergistically improve palliation. This article reviews the rationale, indications and monitoring of standard-dose samarium and investigational high-dose 153Sm-EDTMP treatment of cancer involving bone.

pharmacology & pharmacy
3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT

Astrid Gosewisch,Harun Ilhan,Sebastian Tattenberg,Andrea Mairani,Katia Parodi,Julia Brosch,Lena Kaiser,Franz Josef Gildehaus,Andrei Todica,Sibylle Ziegler,Peter Bartenstein,Guido Böning

DOI: https://doi.org/10.1186/s13550-019-0548-z

IF: 3.434

2019-08-14

EJNMMI Research

Abstract:<h3 class="Heading">Background</h3><p class="Para">The bone marrow (BM) is a main risk organ during Lu-177-PSMA ligand therapy of metastasized castration-resistant prostate cancer (mCRPC) patients. So far, BM dosimetry relies on <em class="EmphasisTypeItalic">S</em> values, which are pre-computed for reference anatomies, simplified activity distributions, and a physiological BM distribution. However, mCRPC patients may show a considerable bone lesion load, which leads to a heterogeneous and patient-specific activity accumulation close to BM-bearing sites. Furthermore, the patient-specific BM distribution might be significantly altered in the presence of bone lesions. The aim was to perform BM absorbed dose calculations through Monte Carlo (MC) simulations and to investigate the potential value of image-based BM localization.</p><p class="Para">This study is based on 11 Lu-177-PSMA-617 therapy cycles of 10 patients (10 first cycles), who obtained a pre-therapeutic Ga-68-PSMA-11 PET/CT; quantitative Lu-177 SPECT acquisitions of the abdomen 24 (+CT), 48, and 72 h p.i.; and a Lu-177 whole-body planar acquisition at 24 h post-therapy. Patient-specific 3D volumes of interest were segmented from the Ga-68-PSMA-11 PET/CT, filled with activity information from the Lu-177 data, and imported into the FLUKA MC code together with the patient CT. MC simulations of the BM absorbed dose were performed assuming a physiological BM distribution according to the ICRP 110 reference male (MC1) or a displacement of active BM from the direct location of bone lesions (MC2). Results were compared with those from <em class="EmphasisTypeItalic">S</em> values (SMIRD). BM absorbed doses were correlated with the decrease of lymphocytes, total white blood cells, hemoglobin level, and platelets. For two patients, an additional pre-therapeutic Tc-99m-anti-granulocyte antibody SPECT/CT was performed for BM localization.</p><h3 class="Heading">Results</h3><p class="Para">Median BM absorbed doses were 130, 37, and 11 mGy/GBq for MC1, MC2, and SMIRD, respectively. Significant strong correlation with the decrease of platelet counts was found, with highest correlation for MC2 (MC1: <em class="EmphasisTypeItalic">r</em> = − 0.63, <em class="EmphasisTypeItalic">p</em> = 0.04; MC2: r = − 0.71, <em class="EmphasisTypeItalic">p</em> = 0.01; SMIRD: <em class="EmphasisTypeItalic">r</em> = − 0.62, <em class="EmphasisTypeItalic">p</em> = 0.04). For both investigated patients, BM localization via Tc-99m-anti-granulocyte antibody SPECT/CT indicated a displacement of active BM from the direct location of lesions similar to model MC2 and led to a reduction in the BM absorbed dose of 40 and 41% compared to MC1.</p><h3 class="Heading">Conclusion</h3><p class="Para">Higher BM absorbed doses were observed for MC-based models; however, for MC2, all absorbed doses were still below 2 Gy. MC1 resulted in critical values for some patients, but is suspected to yield strongly exaggerated absorbed doses by neglecting bone marrow displacement. Image-based BM localization might be beneficial, and future studies are recommended to support an improvement for the prediction of hematoxicities.</p>

radiology, nuclear medicine & medical imaging
Timing And Optimized Acquisition Parameters For The Whole-Body Imaging Of Lu-177-Edtmp Toward Performing Bone Pain Palliation Treatment

Congjin Liu,James Robert Brasic,Xingdang Liu,Hongyu Li,Xueqin Xiang,Zhifu Luo,Yuankai Wang,Dayu Kuai,Guangming Zhang,John J. Zaknun

DOI: https://doi.org/10.1097/MNM.0b013e32834d3c13

2012-01-01

Nuclear Medicine Communications

Abstract:Objectives Lutetium-177-labeled ethylenediamine-N,N,N',N'-tetrakis (methylene phosphonic acid) (Lu-177-EDTMP), a beta-emitting bone-seeking therapeutic radiopharmaceutical being assessed as an agent for palliation of bone pain, can emit suitable gamma-photons for scintigraphy. This investigation sought to characterize its optimal conditions for whole-body gamma camera imaging in patients.Materials and methods Eleven patients with bone metastases underwent whole-body bone scanning using both Tc-99m-methyl-diphosphonate (Tc-99m-MDP) and Lu-177-EDTMP (29.4 +/- 12.5MBq/kg BW) utilizing a dual-head camera. For lutetium-177 imaging, two types of collimators, low-energy high-resolution (LEHR) and medium-energy general-purpose (MEGP), and two different peak energies of 113 and 208 keV were used.Results The femur-to-muscle uptake ratio (F/M) of Tc-99m-MDP was 2.69 +/- 1.06. For Lu-177-EDTMP, the significantly highest F/Ms were found at 24 h (12.59 +/- 5.73) and 48 h (12.54 +/- 5.23) by applying MEGP collimators and collecting the 208 keV photons. In all the combinations of collimator and peak energy, the F/Ms at 24 and 48 h are significantly higher than those at 1 h, except the combination of LEHR collimator and 208 keV peak energy. Lesion-to-normal bone uptake ratios of the Tc-99m-MDP bone scan and images at the 24 and the 48-h phases of Lu-177-EDTMP were analyzed. MEGP and 208 keV had significantly higher values in lesion-to-normal bone uptake ratios. The combination of LEHR and 208 keV provided the poorest images.Conclusion Lu-177-EDTMP can provide fine whole-body images with the best results when applying mediumenergy collimation and collecting the 208 keV energy photons and alternatively by collecting both 208 and 113 keV photons for higher count statistics. The most appropriate time point for imaging is around 24 h after injection. Nucl Med Commun 33:90-96 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases.

Aiping Cheng,Shaoliang Chen,Ying Zhang,Duanzhi Yin,Mengjie Dong

DOI: https://doi.org/10.1089/cbr.2010.0873

2011-01-01

Cancer Biotherapy and Radiopharmaceuticals

Abstract:Purpose: This study evaluated the tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate ((188)Re-HEDP) in patients with different types of advanced cancer suffering from bone pain caused by osseous metastases. Methods: Sixty-four patients received a single injection of escalating doses of (188)Re-HEDP with various dosages. Vital signs were observed before and after treatment for 8 weeks; adverse effects and rebound pain were recorded within 8 weeks after injection. Blood counts, biochemical parameters, and electrocardiogram were also measured over a period of 8 weeks. Clinical follow-up studies including the bone pain score and the Karnofsky performance score were performed. Pain response was scored by a four-point pain-rating scale as complete, marked, mild, and no response. Results: No adverse effects or clinically significant changes in vital signs, electrocardiograms, and biochemical parameters in patients were observed, and there was no statistical change in alkaline phosphate levels in patients before or after treatment. The overall nadir of thrombopenia was at week 4, leucopoenia at week 3, and anemia at week 8. At week 8, the mean level of platelets and leukocytes returned to baseline levels. The pain score descended from 8.11 to 7.74 on the day of therapy, with a nadir of 4.89 at week 4, and up to 6.67 at week 8 after therapy (p<0.05). The Karnofsky performance score continually increased from 74.81 before therapy to 82.31 at 8 weeks (p<0.05). Pain palliation was reported by 73.33% of patients, with a mean duration of 6.85 weeks and a mean start time of 4.05 days. Of the specific tumor types, pain relief was achieved in 84.62% of patients with prostate cancer, 78.57% with breast cancer, 62.50% with lung cancer, and 55.56% with liver cancer. Conclusions: (188)Re-HEDP is a useful radiopharmaceutical agent for improving bone pain in patients with advanced cancer with painful bone metastases.
Dosimetry at cellular level for the alpha-emitting radionuclides actinium-225, astatine-211 and radium-223 for bone metastasis cells from castration resistant prostate cancer

Catherine Costa Oliveira-Silva,Mateus S Maillard,Raoni Silva,Lidia Vasconcelos de Sá

DOI: https://doi.org/10.1088/1361-6560/ad7b9a

IF: 3.5

2024-09-21

Physics in Medicine and Biology

Abstract:Objectives The aim is to evaluate energy deposition in the nucleus and cytoplasm in targeted alpha therapy of metastatic castration-resistant prostate cancer by modeling two cell lines, PC3 (osteolytic) and LNCaP C4-2 (osteoblastic), for actinium-225, astatine-211, and radium-223 and their progeny, using Monte Carlo simulations with the GATE/Geant4 code. Approach We developed single cell and cell clusters models and couple them to Monte Carlo simulations performed on the GATE platform version 9.3, setting the GEANT4-DNA physics list emstandard_opt3_mixed_dna for At-211, Ac-225 and Ra-223 progenies. We considered three radionuclide distributions as a sources: the nucleus, the cytoplasm and the whole cell. Main Results When the nucleus was considered as a target, the S-values (N←N) calculated for At-211, Ac-225 and Ra-223 progenies were significantly higher, within 60-90%, than S-values (N←Cy), demonstrating less influence of cytoplasm internalization. When the cytoplasm was considering as a target, the S-values (Cy←Cy) calculated for At-211, Ac-225 and Ra-223 progeny were significantly higher, within 30-90%, than the S-values (Cy←N). When no progeny migration occurs and the nucleus was considered as the target, the cumulative S-values (N←N) calculated for At-211, Ac-225 and Ra-223 were significantly higher, within 50- 70%, than the S-values (N←N) computed for At-211, Ac-225, and Ra-223. Comparing the cumulative S-values, Ac-225 and Ra-223 therapies is more effective, in terms of deposited energy in a target, than that with At-211. Significance The data presented in this research indicates that Ac-225 therapy may be theoptimum choice due to the energy deposited in the nucleus, as long as the recoil effects and redistribution of progeny are understood. In contrast, At-211 is an alternative to avoid progeny migration. However, to completely analyze the efficacy of radionuclide therapy, other parameters must be considered, such as biological half-life, stability of the transport molecule, progeny migration, excretion pathways, and uptake in different organs.

engineering, biomedical,radiology, nuclear medicine & medical imaging
Production, quality control, and determination of human absorbed dose of no carrier added 177 Lu-risedronate for bone pain palliation therapy

Nafise Salek,Mohsen Mehrabi,Simindokht Shirvani Arani,Ali Bahrami Samani,Mostafa Erfani,Sara Vosoghi,Mohammad Ghannadi Maragheh,Mojtaba Shamsaei

DOI: https://doi.org/10.1002/jlcr.3466

Abstract:In this study, the radiocomplexation of risedronic acid, a potent bisphosphonate with a no carrier added (NCA) 177 Lu, was investigated and followed by quality control studies, biodistribution evaluation, and dosimetry study for human based on biodistribution data in Wistar rats. The moderate energy β- emitter, 177 Lu (T½ = 6.7 days, Eβmax = 497 keV), has been considered as a potential agent for development of bone-seeking radiopharmaceuticals. Because the specific activity of the radiolabeled carrier molecules should be high, the NCA radionuclides have an effective role in nuclear medicine. Many researchers illustrated an NCA 177 Lu production; among these separation techniques, extraction chromatography has been considered more capable than other methods. The NCA 177 Lu was produced with specific activity of 48 Ci/mg and radionuclidic purity of 99.99% by the irradiation of enriched 176 Yb target in thermal neutron flux of 4 × 1013 n·cm-2 ·s-1 for 14 days. The NCA 177 Lu was mixed to a desired amount of sodium risedronate (15 mg/mL, 200 μL) and incubated with stirring at 95°C for 30 minutes. The radiochemical purity of 177 Lu-risedronate was determined by radio thin-layer chromatography, and high radiochemical purities (>97%) were obtained under optimized reaction conditions. The complex was injected to Wistar rats, and complex biodistribution was performed 4 hours to 7 days postinjections showing high bone uptake (9.8% ± 0.24% ID/g at 48 hours postinjection). Also, modeling the radiation dose delivery by RADAR software for the absorbed dose evaluation of each human organ showed a major accumulation of the radiocomplex in bone tissue.
Impact of different models based on blood samples and images for bone marrow dosimetry after 177Lu-labeled somatostatin-receptor therapy

Delphine Vallot,Séverine Brillouet,Séléna Pondard,Lavinia Vija,Jean-Sébastien Texier,Lawrence Dierickx,Frédéric Courbon

DOI: https://doi.org/10.1186/s40658-024-00615-5

2024-04-03

EJNMMI Physics

Abstract:Peptide receptor radionuclide therapy with 177 Lu-DOTATATE is a recognized option for treating neuroendocrine tumors and has few toxicities, except for the kidneys and bone marrow. The bone marrow dose is generally derived from a SPECT/CT image-based method with four timepoints or from a blood-based method with up to 9 timepoints, but there is still no reference method. This retrospective single-center study on the same cohort of patients compared the calculated bone marrow dose administered with both methods using mono, bi- or tri-exponential models. For the image-based method, the dose was estimated using Planetdose© software. Pearson correlation coefficients were calculated. We also studied the impact of late timepoints for both methods.

radiology, nuclear medicine & medical imaging
The Comparison of Radionuclide Therapy With 153Sm-EDTMP and Chemotherapy With Pamidronate Disodium in the Patients With Painful Metastatic Bone Cancer

王荣福,朱绍莉,朱玫

DOI: https://doi.org/10.3969/j.issn.1000-7512.2002.02.012

2002-01-01

Abstract:To compare the therapeutic efficacy of radionuclide therapy with 153 Sm-EDTMP and chemotherapy with pamidronate disodium (PD) in the patients with painful metastatic bone cancer, eighteen patients histogically confirmed malignancy with multifocal bone metastases are randomized into the group 153Sm(9 patients treated with 153Sm-EDTMP) and the group PD (9 patients treated with PD) prior to study. The pain score in each patient prior to therapy is more than 6 according to scoring standardization bone pain situation and therapeutic response is classified as 4 grade (inefficient, better, effective and excellent relief). The results show that 7 of 9 patients ettective, 2 cases better, and the therapeutic effective rate is 77. 8% in the group 153Sm; 4 cases inefficient, 1 case better, 3 cases effective and 1 case excellent relief, and the therapeutic effective rate is 44. 4% in the group PD. No hematological toxicity is noted. The results revealed that the therapeutic effective rate of 153Sm-EDTMP is similar to that of pamidronate disodium (P = 0. 334 8), with pain relief maintaining more than 3 weeks, but its incidence of slightly side effect of blood toxicity is more significant than that of pamidronate disodium.
Iodine-125 seed implantation combined with arterial chemoembolization therapy for pain palliation in metastatic bone cancer: a retrospective study.

Zeran Yang,Guang Chen,Ye Cui,Tianhao Su,Jianan Yu,Guowen Xiao,Yanjing Han,Long Jin

DOI: https://doi.org/10.1080/15384047.2018.1523847

2019-01-01

Cancer Biology & Therapy

Abstract:Bone metastases are the most common sites for malignant tumors. Patients who failed to respond to initial first-line treatment with bisphosphonates usually suffer from extreme pain. The aim of this study was to observe the efficacy of arterial chemoembolization combined with Iodine-125 seed implantation in the treatment of bone metastatic cancer pain. All 14 patients with metastatic bone tumor wo failed first-line treatment underwent arterial chemoembolization the day before the implantation of the particles. A computer stereoscopic TPS was used to design the treatment plans, the number and dose of particles required for implantation. Pain relief was evaluated using several parameters such as Visual Analog Scale (VAS) and Verbal Rating Scales (VRS). Pain intensity was measured pre-operation and 1-week, 1-month, 3-month after the treatment. Meanwhile, we also assessed tumor size using computer tomography (CT). Pain palliation was observed in 35.7% (5/14), 57.1% (8/14), and 78.6% (11/14) of all patients at 1-week, 1-month and 3-month post treatment. Likewise, our analysis showed that the combination therapy resulted in a significant decrease of VAS score (6.71 +/- 0.49 before treatment vs 3.36 +/- 0.40 at 3 month post treatment) and overall responding rate of 92.0% using VRS pain assessment. Consistently, tumor size was reduced from 42.16 +/- 10.32 before treatment to 29.11 +/- 8.73 at 3 months post treatment. No serious complications were detected. Our study demonstrate that the combination of arterial chemoembolization and I-125 particles resulted in evident pain relief and reduction of tumor burden, suggesting that the combination treatment could be a feasible and promising therapy for bone tumor management.
89Srcl2 in the Treatment of Cancer Patients with Bone Metastasis and Pain

Da Sun,Yu Chu,Cen Lou,Qian-jun Wang,Hong-wei Zhan,Gang-qiang He

DOI: https://doi.org/10.3760/j.issn:0253-3766.2005.08.015

2005-01-01

Abstract:OBJECTIVE:To evaluate the clinical value of (89)SrCl(2) (Ke xing Inc, Shanghai) as a palliative therapy modality for cancer patients with bone metastasis.METHODS:In 504 cancer patients with painful limitation of movement due to bony metastasis, a dose of 1.48-2.22 MBq/kg (40-60 uCi/kg) iv infusion of (89)SrCl(2) was given.RESULTS:In 97 patients (19.2%) there was no improvement in pain and life quality, 298 patients (59.1%) showed mild to moderate improvement (moderately effective), 109 patients (21.6%) became free of pain and were subsequently fully ambulatory (markedly effective). The pain relief appeared from D1-D46 after (89)SrCl(2) administration, most frequently from D5-D14. The palliative effect could last for about 56 days to 13 months. Repeated bone scans of some patients showed that the metastatic foci in the bone became smaller or even disappeared gradually after the administration of (89)SrCl(2). Approximately 55% of patients experienced grade I approximately III bone marrow depression attributable to (89)SrCl(2), which would return to the pre-treatment level within 3 approximately 9 months.CONCLUSION:(89)SrCl(2) is effective and safe for the relief of bone pain and improvement of quality of life in cancer patients with painful bony metastasis.
Development of [ 64 Cu]Cu-BPAMD for PET imaging of bone metastases

Samaneh Zolghadri,Fateme Badipa,Hassan Yousefnia,Zahra Shiri-Yekta

DOI: https://doi.org/10.1515/ract-2023-0236

2024-03-07

Radiochimica Acta

Abstract:In this study, preclinical evaluation and dosimetric estimation of [ 64 Cu]Cu-BPAMD, as a new bone-seeking agent for PET imaging, was studied. [ 64 Cu]Cu-BPAMD was produced with a specific activity of 8.7 GBq/μmol and radiochemical purity (R.P.) of >98 %. The HA binding results showed the binding of nearly all [ 64 Cu]Cu-BPAMD complex to HA at about 15 mg. Biodistribution studies in the male Syrian rats indicated considerable accumulation in the bone with negligible uptake in the other organs. The bone surface and the bone marrow receiving 0.199 and 0.092 mGy/MBq, respectively, are the organs with the most absorbed dose. This study confirms the production of [ 64 Cu]Cu-BPAMD with high R.P. showing high potential for PET-imaging of bone metastases. The lower absorbed dose of mainly human organs compared to 68 Ga-BPAMD can be considered one of the advantages of this new radiolabeled compound.

chemistry, inorganic & nuclear,nuclear science & technology
EXTRACTION AND EVALUATION OF ISAPGHULA SEED POLYMER AS PHARMACEUTICAL EXCIPIENT

P. Nagar,Parvez Nayyar,P. Sharma

DOI: https://doi.org/10.22270/JDDT.V4I3.856

2014-05-15

Abstract:Aim of study . Present study includes extraction and characterization the isapghula (Plantago Ovata) seed polymer as pharmaceutical excipients. Material and methods: By using water based extraction by heating mental isapghula seed polymer was obtained. For characterization of the extracted isapghula seed polymer phyto chemical screening was done and micromeritic properties, flow behavior, Solid forming capacity of polymer was also evaluated. Results: The result predicts that extracted isapghula seed polymer was soluble in warm water while insoluble in cold water and in organic solvents. It was also exhibited that extracted isapghula seed polymer had good flow properties. pH was found 7.3, this showed that can be used in dosage form without any irritation. Results also showed that this polymer can be used to tablets binder. Conclusions: From the results it was concluded that evaluated parameters showed that isapghula derived seed polymer can be used as pharmaceutical excipient to prepare solid as well as semisolid dosage form. Key words: Isapghula seed polymer, extraction, characterization, natural polymer, pharmaceutical excipients.
Safety and Efficacy of 68Ga- or 177Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases

Lin Qiu,Yingwei Wang,Hanxiang Liu,Qixin Wang,Lin Chen,Lin Liu,Li Wang,Yue Feng,Yue Chen

DOI: https://doi.org/10.1097/rlu.0000000000004634

IF: 10.6

2023-03-27

Clinical Nuclear Medicine

Abstract:PURPOSE: We designed and synthesized a novel theranostic bisphosphonate radiopharmaceutical ( 68 Ga- or 177 Lu-labeled DOTA-ibandronic acid [ 68 Ga/ 177 Lu-DOTA-IBA]) for bone metastasis. In this study, the dosimetry, safety, and efficacy of 68 Ga/ 177 Lu-DOTA-IBA as a theranostic radiopharmaceutical for bone metastases were evaluated in patients with malignancy based on 68 Ga- and 177 Lu-DOTA-IBA images, blood samples, and dosimetric analysis.PATIENTS AND METHODS: Eighteen patients with bone metastasis and progression under conventional therapies were included in this study. Baseline 99m Tc-MDP SPECT and 68 Ga-DOTA-IBA PET/CT were performed for comparative purposes within 3 days. After receiving 891.5 ± 301.3 MBq 177 Lu-DOTA-IBA, serial 177 Lu-DOTA-IBA SPECT bone scan was performed over 14 days. Dosimetric evaluation was performed for main organs and tumor lesions. Safety was assessed by blood biomarkers. Karnofsky Performance Status, pain score, and follow-up 68 Ga-DOTA-IBA PET/CT were performed for response evaluation.RESULTS: Baseline 68 Ga-DOTA-IBA PET demonstrated a higher efficacy for detecting bone metastases compared with 99m Tc-MDP SPECT. The time-activity curves showed fast uptake and high retention of 177 Lu-DOTA-IBA in bone metastases (24 hours: 9.43 ± 2.75 %IA; 14 days: 5.45 ± 2.52 %IA). Liver, kidneys, and red marrow time-activity curves revealed a low uptake and fast clearance. The radiation-absorbed dose in bone metastasis lesions (6.40 ± 2.13 Gy/GBq) was significantly higher than that in red marrow (0.47 ± 0.19 Gy/GBq), kidneys (0.56 ± 0.19 Gy/GBq), or liver (0.28 ± 0.07 Gy/GBq), with all P 's < 0.001. Compared with baseline level, only one patient developed new grade 1 leukopenia (toxicity rate, 6%). The 177 Lu-DOTA-IBA therapy had no statistically significant effect on bone marrow hematopoietic function, liver function, and kidney function at any follow-up visit. Bone pain palliation was achieved in 82% (14/17) of patients. The 8-week follow-up 68 Ga-DOTA-IBA PET/CT demonstrated partial response in 3 patients, disease progression in 1 patient, and stable disease in 14 patients.CONCLUSIONS: 68 Ga/ 177 Lu-DOTA-IBA provides a set of potential theranostic radiopharmaceuticals and may have a good prospect for the management of bone metastasis.

radiology, nuclear medicine & medical imaging

[Revision surgery in episcleral glaucoma drainage devices].

Optimal production and purification of n.c.a.143Pr as a promising palliative agent for the treatment of metastatic bone pain

Efficacy And Safety Of Lu-177-Edtmp In Bone Metastatic Pain Palliation In Breast Cancer And Hormone Refractory Prostate Cancer A Phase Ii Study

Effects of different doses 177Lu-EDTMP for painful bone metastases from prostate and breast cancer

A Comparative Study of Samarium-153-Ethylenediaminetetramethylene Phosphonic Acid with Pamidronate Disodium in the Treatment of Patients with Painful Metastatic Bone Cancer

Clinical observation of ~(153)Sm-EDTMP in treatment of painful bone metastasis in cancer patients

177 Lu-Edtmp For Bone Pain Palliation In Metastatic Prostate And Breast Cancer: A Phase Ii Trial

Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT

Samarium for osteoblastic bone metastases and osteosarcoma

3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT

Timing And Optimized Acquisition Parameters For The Whole-Body Imaging Of Lu-177-Edtmp Toward Performing Bone Pain Palliation Treatment

The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases.

Dosimetry at cellular level for the alpha-emitting radionuclides actinium-225, astatine-211 and radium-223 for bone metastasis cells from castration resistant prostate cancer

Production, quality control, and determination of human absorbed dose of no carrier added 177 Lu-risedronate for bone pain palliation therapy

Impact of different models based on blood samples and images for bone marrow dosimetry after 177Lu-labeled somatostatin-receptor therapy

The Comparison of Radionuclide Therapy With 153Sm-EDTMP and Chemotherapy With Pamidronate Disodium in the Patients With Painful Metastatic Bone Cancer

Iodine-125 seed implantation combined with arterial chemoembolization therapy for pain palliation in metastatic bone cancer: a retrospective study.

89Srcl2 in the Treatment of Cancer Patients with Bone Metastasis and Pain

Development of [ 64 Cu]Cu-BPAMD for PET imaging of bone metastases

EXTRACTION AND EVALUATION OF ISAPGHULA SEED POLYMER AS PHARMACEUTICAL EXCIPIENT

Safety and Efficacy of 68Ga- or 177Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases